MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202441016018 A) filed by Dr. P. Anandan; Dr. N. Anbuselvan; and Dr. Bhaskarrao Yakkala, Chennai, Tamil Nadu, on March 7, 2024, for 'fabrication of highly sensitive biosensors for early detection of breast cancer biomarkers.'
Inventor(s) include Dr. P. Anandan; Dr. N. Anbuselvan; and Dr. Bhaskarrao Yakkala.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "Breast cancer remains a global health challenge, emphasizing the critical need for early and accurate diagnostic methods. This research focuses on the development of highly sensitive biosensors to detect specific biomarkers associated with early-stage breast cancer, aiming to revolutionize early detection and improve patient outcomes.The biosensor fabrication involves the integration of advanced nanomaterials and state-of-the-art sensing technologies. We employ a multi-disciplinary approach, combining nanotechnology, materials science, and biochemistry to enhance the sensitivity and specificity of the biosensors. The platform is designed to target key biomarkers such as HER2 (human epidermal growth factor receptor 2), CA 15-3 (cancer antigen 15-3), and BRCA1 (breast cancer gene 1), which are known indicators of breast cancer progression.The sensor's architecture incorporates nanostructured materials with unique electrical, optical, or electrochemical properties, enabling the selective and precise detection of biomolecules at ultra-low concentrations. Surface modification techniques are employed to optimize the sensor's biocompatibility and ensure a high binding affinity for the target biomarkers. Additionally, signal amplification strategies are implemented to enhance the detection limit, enabling the identification of biomarkers at the earliest stages of breast cancer development.The developed biosensor demonstrates outstanding sensitivity, specificity, and reproducibility, making it a promising tool for early breast cancer diagnosis. Preliminary experimental results indicate the successful detection of breast cancer biomarkers in complex biological samples, showcasing the sensor's potential for clinical applications. Furthermore, the biosensor's scalability and cost-effectiveness make it a viable candidate for widespread use in both clinical settings and point-of-care diagnostics.This research contributes to the ongoing efforts in advancing early cancer detection technologies, offering a promising avenue for improving patient outcomes through timely intervention and personalized treatment strategies. The development of highly sensitive biosensors represents a significant step forward in the fight against breast cancer, with potential implications for other cancer types and diseases."
Disclaimer: Curated by HT Syndication.
